His main research goal is to find clinical applications for MS genetic discoveries, especially to find molecular biomarkers to aid clinical management of MS, including for therapeutic response. Notably, his group has now identified three immune cell types of MS, and is testing their clinical applicability. They have also identified the likely mechanism for the association of the vitamin D genes with MS, and are investigating how to use this information to better use the vitamin D pathway to reduce MS risk. His group aims to translate their genetic discoveries in other diseases, notably chronic hepatitis C disease, into clinical practice. They provide a genetic testing service based on their research findings for drug response for this disease, and for familial amyloidosis.